Agios Pharma (NASDAQ: AGIO) announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Agios Pharma (AGIO) Releases Initial AG-120 Data; Oppenheimer Reiterates Perform November 9, 2015 9:28 AM Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid TumorsNovember 8, 2015 8:01 AM Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid TumorsNovember 8, 2015 8:01 AM